UTILIZATION MANAGEMENT MEDICAL POLICY
Defines prior authorization recommendation, coverage criteria, dosing regimens, prescriber requirements, approval duration, and non-covered circumstances for Empliciti (elotuzumab) when used for multiple myeloma under the medical benefit.
Annual revision 04/09/2025 with no criteria changes.
Coverage Summary
Coverage stance: Covered with criteria for the FDA‑approved indication of multiple myeloma. Approval is for 1 year when the listed criteria are met. Minimum age for approval is ≥18, and Empliciti must be prescribed by or in consultation with an oncologist or hematologist.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.